![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1479955
¾È¾Ð°è ½ÃÀå : ¿¹Ãø(2024-2029³â)Tonometer Market - Forecasts from 2024 to 2029 |
¾È¾Ð°è ½ÃÀåÀº CAGR 3.98%·Î, 2022³â 3¾ï 1,228¸¸ 1,000´Þ·¯¿¡¼ 2029³â¿¡´Â 4¾ï 1,048¸¸ 9,000´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
¾È±¸³» ¾È¾Ð°ú ¾È¾ÐÀº ÈÞ´ë¿ë ÀÇ·á±â±âÀÎ ¾È¾Ð°è¸¦ »ç¿ëÇÏ¿© ÃøÁ¤ÇÕ´Ï´Ù. ¾È¾Ð°è´Â ¾È±¸ Ç¥¸éÀ» ºÎµå·´°Ô ´Û¾ÆÁÖ´Â ±Ý¼Ó Ç÷±Àú°¡ ´Þ¸° ³³ÀÛÇÑ ÇÁ·Îºê·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
³ì³»ÀåÀÌ ½ÉÇØÁö¸é ½Ã½Å°æÀÌ ¼Õ»óµÇ¾î ½Ç¸í¿¡ ´ÞÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾È¾Ð°è´Â Ç÷ç¿À·¹¼¼ÀÎÀ̳ª ±¹¼Ò ¸¶ÃëÁ¦¸¦ »ç¿ëÇÒ Çʿ䰡 ¾ø¾î °¨¿°À̳ª °¢¸· Âû°ú»ó À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ º´¿ø, ¾È°ú Áø·á¼Ò, ¾È°ú ¼¾ÅÍ¿¡¼ ÀÚÁÖ Ã¤ÅÃÇϰí ÀÖ½À´Ï´Ù.
ÀÏ¹Ý Àα¸ÀÇ ³ì³»Àå À¯º´·ü Áõ°¡´Â ¾È¾Ð°è ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ³ëÀΰú ´ç´¢º´ ȯÀÚ Áõ°¡´Â ¾È¾Ð°è ¼ö¿ä ±ÞÁõ¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
ÀÇ·á ±â°ü¿¡¼ ¾ÆÇö󳪽ÿ ¾È¾Ð°è »ç¿ëÀÌ Áõ°¡ÇÏ¸é¼ ¾È¾Ð°è ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â °¢¸·ÀÇ ÀϺθ¦ ÀϽÃÀûÀ¸·Î ÆòÆòÇÏ°Ô ¸¸µå´Â µ¥ ÇÊ¿äÇÑ µµ¼ö¸¦ °áÁ¤Çϱâ À§ÇØ ¾È¾Ð(IOP)À» ÃøÁ¤ÇÏ´Â µ¥ ÀÚÁÖ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ ¸®¹Ù¿îµå Åä³ë¸ÞÆ®¸®ÀÇ ¹ßÀüÀº ¾È¾Ð°è ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
ÃÖ±Ù ¼ö³â°£ Æò±Õ ¼ö¸íÀÌ ±æ¾îÁö¸é¼ ³ëÀÎ Àα¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ç´¢º´, °üÀý¿°, °íÄÝ·¹½ºÅ×·Ñ, °íÇ÷¾Ð µî ±Þ¼º Áúȯ¿¡¼ ¸¸¼ºÁúȯÀ¸·ÎÀÇ º¯È´Â Àΰ£ÀÇ Æò±Õ ¼ö¸í °¨¼ÒÀÇ ¿øÀÎÀÔ´Ï´Ù.
2019³â À¯¿£ ¼¼°è °í·ÉÈ Á¶»ç¿¡ µû¸£¸é 2050³â±îÁö Àü ¼¼°è 65¼¼ ÀÌ»ó ³ëÀÎ Àα¸´Â 15¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ³ëÀμº Áúȯ ¹× ±âŸ ¸¸¼ºÁúȯÀÇ À¯º´·üÀº Àα¸¿Í ÇÔ²² Áõ°¡ÇÏ¿© ¼¼°è ¾È¾Ð°è ½ÃÀåÀÇ È®ÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
³ì³»Àå ¹× ±âŸ ¾È±¸ Àå¾Ö¸¦ À¯¹ßÇÏ´Â ¸¸¼ºÁúȯÀ» Æ÷ÇÔÇÑ ¾È°ú ÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í ½Äº°ÇÏ¸é ½Ã·Â ÀúÇÏ¿Í ½Ç¸íÀ» ÇÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¤±âÀûÀÎ ¾È°ú °ËÁøÀ» ÅëÇØ Àå¾ÖÀÇ Â¡Èĸ¦ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.
³ì³»ÀåÀº Ãʱ⿡´Â Ưº°ÇÑ Áõ»óÀ̳ª °æ°í ½ÅÈ£¸¦ ³ªÅ¸³»Áö ¾Ê½À´Ï´Ù. µû¶ó¼ ³ì³»ÀåÀ» ¿¹¹æÇϱâ À§Çؼ´Â ÀÌ Áúȯ¿¡ ´ëÇÑ ´ëÁßÀÇ Áö½ÄÀ» ³ôÀÌ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. Á¤±âÀûÀÎ ¾È°ú °ËÁø°ú ½Ã·Â ÀúÇϸ¦ ÇÇÇϱâ À§ÇÑ ´ëÃ¥Àº ¼¼°è ¾È¾Ð°è ½ÃÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
¾È¾Ð °Ë»ç´Â ¾È±¸ÀÇ ¾È¾ÐÀ» ÃøÁ¤ÇÏ´Â °Ë»çÀÔ´Ï´Ù. ÀÌ °Ë»ç´Â °¢¸·ÀÇ ÀϺθ¦ ÀϽÃÀûÀ¸·Î ÆòÆòÇÏ°Ô ¸¸µå´Â µ¥ ÇÊ¿äÇÑ ¾Ð·ÂÀ» ÃøÁ¤ÇÕ´Ï´Ù. ³ì³»Àå Áø´Ü¿¡ »ç¿ëµÇ¸ç ¾È¾Ð°è ½ÃÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
¾È¾Ð°èÀÇ È²±Ý Ç¥ÁØÀÎ Ä®ÀÚÀ̽º(Carl Zeiss) µîÀÇ ¾È¾Ð°è´Â °ñµå¸¸ ±³¼ö°¡ Á¦¾ÈÇÑ ¾ÆÀ̵ð¾î¸¦ ¹ÙÅÁÀ¸·Î ¾È¾ÐÀ» Á¤È®ÇÏ°Ô ÃøÁ¤ÇÕ´Ï´Ù. ¾È¾Ð ÃøÁ¤Àº ¸¹Àº ¾È°ú Áúȯ, ƯÈ÷ ³ì³»ÀåÀÇ Áø´Ü°ú Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù.
¶ÇÇÑ ´Ù¸¥ ¾È¾Ð ÃøÁ¤ Àåºñ¿ÍÀÇ ºñ±³ ¿¬±¸¸¦ ÅëÇØ ³ì³»Àå Áø´Ü¿¡ È¿°úÀûÀ̶ó´Â Á¡ÀÌ °Á¶µÇ¸é¼ ¾È¾Ð ÃøÁ¤¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 8¿ù Canadian Journal of Ophthalmology¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é ÈÞ´ë¿ë ¾È¾Ð ÃøÁ¤ Àåºñ´Â ¾È¾ÐÀ» °ú¼ÒÆò°¡ÇÏ´Â °æ¿ì°¡ ¸¹¾Æ ¾È¾ÐÀ» °ú¼ÒÆò°¡ÇÏ´Â °æ¿ì°¡ ¸¹´Ù´Â »ç½ÇÀÌ ¹àÇôÁ³½À´Ï´Ù.
ÈÞ´ë¿ë ¾È¾Ð°è·Î ¾È¾ÐÀ» °ú¼ÒÆò°¡ÇÏ¸é ³ì³»ÀåÀÇ °ú¼ÒÁø´Ü°ú °ú¼ÒÄ¡·á·Î À̾îÁ® µ¹ÀÌų ¼ö ¾ø´Â ½Ã·ÂÀúÇÏ·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ÈÞ´ë¿ë ¾È¾Ð°è¿Í ºñ±³ÇÏ¿© ¾È¾ÐÀ» °ú´ëÆò°¡ÇÏ´Â °æÇâÀÌ ÀÖ´Â ¾ÆÇö󳪽ÿ ¾È¾Ð°è´Â ¾È¾ÐÀ» °ú´ëÆò°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
»ó¾÷Àû, ¹Ý°ü¹Ý¹Î°£ ¹× °ø°ø ÀÇ·á ºÎ¹®¿¡¼ °èȹÇϰí ÀÖ´Â ³ì³»Àå °ËÁø ÇÁ·Î±×·¥ Áõ°¡´Â ¿¹Ãø ±â°£ Áß ¾È¾Ð°è »ê¾÷ÀÇ ¹ßÀüÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾È°ú °ËÁø Ä·ÇÁ Áõ°¡·Î ÀÎÇÑ ³ì³»Àå ¹× ½Ã·Â¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ Áö½ÄÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾È¾Ð°è¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¾È°ú °ËÁø ÇÁ·Î±×·¥ Áõ°¡´Â ¾È°ú °ËÁø ÇÁ·Î±×·¥ Áõ°¡µµ ¾È¾Ð°è ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Vision 2020: The Right to Sight-India´Â Áö¿ª ¾È°ú¿¡ °üÇÑ Àü±¹ ÄÁÆÛ·±½º¸¦ °³ÃÖÇÏ°í ¹«·á ¾È°ú °ËÁø Ŭ¸®´ÐÀ» °³ÃÖÇÏ¿© ¾È°ú Áø·á¿Í ±× ¼º°øÀ» À§ÇÑ Ç÷§ÆûÀ» Á¦°øÇß½À´Ï´Ù.
°¢¸·ÀÇ »ýÈÇÐÀû Ư¼º¿¡ ÀÇÁ¸ÇÏÁö ¾Ê´Â Dynamic Contour Tonometer(DCT), Ocular Response Analyzer(ORA)¿Í °°Àº Ź»ó¿ë ¾È¾Ð°è°¡ ¾È¾Ð ÃøÁ¤¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾È¾Ð°è ½ÃÀåÀº °¢¸· ¼ºÇü¼ú, ³ì³»Àå, ¹é³»Àå ¹× ±âŸ ±¼Àý ±³Á¤ ¼ö¼ú°ú °°Àº ¾È°ú ¼ö¼úÀÌ ´Ã¾î³²¿¡ µû¶ó ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ·¯ÇÑ Áúº´À» È¿°úÀûÀ¸·Î Ä¡·áÇϰí ÇâÈÄ ÀÇ·á ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ ¾È¾Ð ÃøÁ¤Àº °¢¸·ÀÇ »ýü ¿ªÇÐÀû Ư¼º¿¡ ´ëÇÑ Ã¶ÀúÇÑ ºÐ¼®À» ¼ö¹ÝÇÕ´Ï´Ù. ½ÃÁß¿¡¼ ÆÇ¸ÅµÇ´Â ÈÞ´ë¿ë ¾È¾Ð°è¿¡´Â ¸®¹Ù¿îµå ¾È¾Ð°è, ÆÛŲ½º ¾È¾Ð°è, Åä³ëÆæ µîÀÌ ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ Áß ÈÞ´ë¿ë ¾È¾Ð°èÀÇ È޴뼺, »ç¿ë ÆíÀǼº ¹× ȯÀÚ ÆíÀǼº Çâ»ó°ú °°Àº ¿äÀÎÀÌ ¾È¾Ð°è ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾È¾Ð°è ½ÃÀåÀº ºÒÇÊ¿äÇÑ ½Ã·Â ÀúÇϸ¦ ¿¹¹æÇϱâ À§ÇÑ Á¶±â Áø´Ü°ú Á¤±âÀûÀÎ ¾È¾Ð(IOP) ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ È¯ÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯ÀÍÇÑ ÁöºÒ ±ÔÄ¢ÀÌ µµÀÔµÇ¸é º´¿ø ¹× Ŭ¸®´Ð¿¡¼ ¾È¾Ð°è »ç¿ëÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹¸¦ µé¾î ÆÄ½ºÄ® µ¿Àû À±°û ¾È¾Ð°è¿Í °°Àº °£´ÜÇÑ ¾È¾Ð°è¿Í º¹ÀâÇÑ ¾È¾Ð°è ¸ðµÎ ¹Ì±¹¿¡¼´Â Ä«Å×°í¸® III CPT 0198T·Î º¸Çè»ç À¯³ªÀÌÆ¼µå ÇコÄɾ ºñ¿ëÀ» ºÎ´ãÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ Áß ºÏ¹Ì°¡ ¾È¾Ð°è ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡´Â ´ë±â¾÷ÀÌ Á¸ÀçÇÏ°í ³ì³»Àå ¹ßº´·üÀÌ ³ôÀ¸¸ç ÀÇ·á ½Ã½ºÅÛÀÌ Àß ±¸ÃàµÇ¾î ÀÖÀ¸¸ç, ¾È¾Ð°è ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î ¸ß½ÃÄÚ º¸°ÇºÎ°¡ 2022³â 11¿ù ¹ßÇ¥ÇÑ º¸°í¼¿¡ µû¸£¸é °°Àº ÇØ ¸ß½ÃÄÚÀÇ ³ì³»Àå ȯÀÚ ¼ö´Â 150¸¸ ¸íÀ¸·Î Ãß»êµË´Ï´Ù. ÀÌ ÁúȯÀº 60¼¼ ÀÌ»óÀÇ ³ëÀε鿡°Ô ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ¶ÇÇÑ ¸ß½ÃÄÚ¿¡¼ °¡Àå ÈçÇÑ ³ì³»ÀåÀº °³¹æ°¢¿ø¹ß³ì³»ÀåÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼ ¸ß½ÃÄÚÀÇ ³ôÀº ³ì³»Àå À¯º´·üÀº ¾È¾Ð°è¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁ® ¿¹Ãø ±â°£ Áß ½ÃÀå ±Ô¸ð°¡ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
¿¬±¸ Çù·Â Áõ°¡¿Í Á¤ºÎ Áö¿øÃ¥µµ ¾È¾Ð°è »ê¾÷ÀÇ È®ÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ´Ù¸¥ ¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹Àº À¯ÀÍÇÑ ÇコÄɾî¹ý, ´ë±Ô¸ð ȯÀÚ ±â¹Ý ¹× È®¸³µÈ ÇコÄÉ¾î »ê¾÷ÀÇ °á°ú·Î ÀÌ Ç÷¾Ð°è ½ÃÀå¿¡¼ °¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The Tonometer market is projected to witness a compound annual growth rate of 3.98% to grow to US$410.489 million by 2029, from US$312.281 million in 2022.
The intraocular and fluid pressure inside the eye is measured using a tonometer, a portable medical device. It consists of metal plunger-equipped flat-tipped probes that are gently brushed on the eye's surface.
It is used to identify and evaluate those at risk of glaucoma, which, in severe cases, can harm the optic nerve and result in blindness. Tonometers don't need fluorescein or topical anesthetic to use, and they lessen the risk of getting infections and corneal abrasions. As a result, hospitals, eye clinics, and ophthalmic centers frequently employ them.
The increased prevalence of glaucoma among the general population is one of the primary drivers of the tonometer market rise. Further fueling the surge in tonometer demand is the growing elderly and diabetic populations, who are more vulnerable to eye-related conditions.
The increased use of applanation tonometry in healthcare facilities is also fueling tonometer market growth. The test is frequently used to determine intraocular pressure (IOP) since it determines how much power is required to temporarily flatten a section of the cornea. Additionally, rebound tonometry's advancement is promoting tonometer market growth.
Since the population's life expectancy has grown over the past several years, there are more elderly people in society. A change from acute to chronic disorders including diabetes, arthritis, high cholesterol, and hypertension, is the reason for the decrease in life expectancy of humans.
According to a 2019 United Nations World Ageing study, there will be 1.5 billion people who are 65 years of age or older worldwide by the year 2050. The prevalence of geriatric and other chronic illnesses would rise along with the population, which will propel the expansion of the worldwide tonometer market.
Vision loss and blindness might be avoided via early identification of and detection of ophthalmic disorders including glaucoma and other chronic diseases causing eye difficulties. The signs of the disorders might be identified with routine eye exams.
Glaucoma does not initially exhibit any particular symptoms or warning signals. Therefore, raising public knowledge of the condition may be crucial in preventing it; regular eye exams and measures to avoid vision loss further boost the worldwide tonometer market.
The applanation tonometry test determines the eye's intraocular fluid pressure. The test measures the pressure needed to temporarily flatten a section of the cornea. It is employed in glaucoma diagnosis and is fueling the tonometer market.
The gold standard in tonometry, applanation tonometers from firms like Carl Zeiss give accurate measures of intraocular pressure (IOP) based on the idea presented by Professor Goldmann. IOP measurement is an essential part of the diagnosis and treatment of many eye diseases, particularly glaucoma.
Additionally, the demand for applanation tonometry is anticipated to rise due to comparative studies with other tonometry devices, highlighting its effectiveness in diagnosing glaucoma. For example, research published in the Canadian Journal of Ophthalmology in August 2022 revealed that handheld rebound tonometry devices often underestimate intraocular pressure (IOP) when compared to applanation tonometry.
This underestimation of IOP with handheld rebound tonometry may result in the underdiagnosis and undertreatment of glaucoma, leading to irreversible vision loss. Consequently, the market is expected to experience significant growth as a result of applanation tonometry's tendency to overestimate IOP compared to handheld rebound tonometry.
A rise in glaucoma screening programs planned by the commercial, semi-public, and public healthcare sectors is anticipated to promote tonometer industry development throughout the projected period. The need for tonometers is driven by the growth in knowledge of glaucoma and its effects on vision brought on by the growing number of eye checkup camps.
Increased eye screening programs are also anticipated to promote tonometer market growth. For instance, Vision 2020: The Right to Sight - India conducted a national conference on community ophthalmology and held free eye screening clinics to provide a platform for eye care practices and their successful administration.
IOP is measured using desktop tonometers like the Dynamic Contour Tonometer (DCT) and Ocular Response Analyzer (ORA), which are not reliant on the biochemical characteristics of the cornea. The tonometer market is anticipated to develop as more eye procedures including keratoplasty, glaucoma, cataract, and other refractive operations are performed.
To effectively treat these diseases and save on future medical expenses, IOP measurements are being accompanied by a thorough analysis of the cornea's biomechanical features. Commercially available portable tonometers include rebound tonometers, Perkins tonometers, and tono-pens. Throughout the forecast period, factors such as the portable tonometer's portability, ease of use, and improved patient comfort are anticipated to propel the tonometer market growth.
The tonometer market is expected to be driven by increased patient awareness of early diagnosis and routine intraocular pressure (IOP) monitoring to prevent unnecessary vision loss. If beneficial payment rules are put in place, tonometer use in hospitals and clinics is anticipated to increase.
For instance, the cost of both simple and complex tonometers, such as the Pascal dynamic contour tonometer, is covered by insurance carrier United Healthcare in the United States under Category III CPT 0198T.
North America is predicted to dominate the tonometer market during the forecast period. The tonometer market is expanding as a result of the existence of large businesses, the high rate of glaucoma in the region, and the established healthcare system.
For example, according to a report released by the Ministry of Health in Mexico in November 2022, it is estimated that there are 1.5 million individuals living with glaucoma in Mexico in the same year. This condition is predominantly observed in individuals aged 60 and above. Furthermore, the most prevalent form of glaucoma in Mexico is reported to be open-angle primary glaucoma. Consequently, the substantial prevalence of glaucoma cases in the country leads to an increased demand for tonometers, which is expected to drive significant market growth throughout the projected period.
Growth in the number of research collaborations as well as supportive government initiatives are some other factors projected to fuel the tonometer industry expansion. The United States is anticipated to hold the highest share in this tonometer market as a result of beneficial healthcare laws, a sizable patient base, and an established healthcare industry.
Market Key Developments